Elbasvir/grazoprevir
< Elbasvir
| Combination of | |
|---|---|
| Elbasvir | NS5A inhibitor |
| Grazoprevir | NS3/4A protease inhibitor |
| Clinical data | |
| Trade names | Zepatier |
| AHFS/Drugs.com | zepatier |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.
Both elbasvir and grazoprevir were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug in January 2016.